The global Meningococcal Vaccine Market size was valued at USD 3.0 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 9.7% from 2021 to 2027.
Growing use of meningococcal vaccines for immunization of special risk groups, including travelers, or military personnel, and for recommended but not-reimbursed immunization, is fueling gains in the market.
Major players in the meningococcal vaccine consist of Pfizer Inc., GlaxoSmithKline Plc., Sanfoli, Novarties AG, Baxter and others.
April 2020- The U.S. Food and Drug Administration (FDA) has approved a Biologics License Application for Meningococcal (Groups A, C, Y, W) Conjugate Vaccine for the prevention of invasive meningococcal disease in persons 2 years of age and older. Approval of this new vaccine in the U.S. represents an important milestone in the ongoing fight to help protect as many people as possible from meningococcal disease. It is their ambition to make this vaccine available to further expand protection to individuals worldwide. MenQuadfi was designed to elicit and demonstrated a high immune response across all four serogroups for multiple ages and was well tolerated. MenQuadfi is intended to protect an expanded age group. Licensure marks MenQuadfi as the only U.S. FDA-approved quadrivalent meningococcal vaccine indicated for persons 2 through 56 years of age and older.1 MenQuadfi is the first and only quadrivalent meningococcal vaccine in the U.S. that uses tetanus toxoid as a protein carrier. It will be available in a ready-to-use liquid formulation allowing healthcare providers to avoid vaccine reconstitution.
Sept 2020- CDC’s Advisory committee on immunization practices (ACIP) for use of meningococcal vaccine in U.S as a comprehensive summary and update of previously published recommendations it replace all previously published reports and policy notes. This recommendation also boosts the seogroup B meningococcal vaccine for persons at increased risk for seogroup B meningococcal disease.
Aug 2020 GSK announces first participant vaccinated in phase 3 clinical trials of its 5-in-1, meningitis ABCWY vaccine candidate. Entering the final stage of clinical trials with our 5-in-1, MenABCWY vaccine candidate is a major step toward GSK’s goal of reducing meningococcal disease around the world. This vaccine candidate builds on the heritage of Bexsero and Menveo and we would like to thank all the scientific researchers, medical partners, advocates and families around the world who also hope for a successful outcome.
March 2020 University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine.
Pfizer Inc. Jun 2020 announced the initiation of four phase3 clinical trials within its current pipeline of investigational vaccines. Two studies of the 20-valent pneumococcal polysaccharide conjugate vaccine candidate, 20vPnC, evaluating four-dose series infants starting at2 months of age. Both studies will expand the data on the safety and tolerability of the investigational vaccine in infants and include a control group of Prevnar13. Second study has the goal of determining immunologic noninferiority between 20vPnc and Prevnar13, a critical requirement for vaccine licensure.
On the Basis of type the meningococcal disease vaccine market has segmented into meningococcal conjugate (MenACWY), seogroup B meningococcal (MenB) and others. On the basis of end user, it includes hospitals, clinics and others. On the basis of distribution channel it has hospital pharmacy, retail pharmacy and others. On the basis of region it has included North America, Europe, Asia-Pacific and Row. Among these North America dominated the market and accounted for a revenue share of 48.0% in 2020. Favorable recommendations and support from government and high investments in R&D are some factors driving the North American market.